Insights

Through in silico analysis, we’ve confirmed Biomeme’s SARS-Cov-2 assay detects all current variants of concern and variants of interest including delta and omicron. Omicron was first identified in...

Each year, the University City Science Center’s Nucleus Awards bring together the region’s leaders and groundbreakers in innovation, all while supporting Philadelphia’s future as a hub of innovation...

Biomeme is excited to announce that we have signed a definitive agreement to acquire Predigen, a spin-out from Duke University and global leader in the development of host gene expression signatures...

Biomeme’s move into its new corporate headquarters at Netrality's 401 North Broad Street, will begin an exciting new chapter for our company. Our new headquarters were announced earlier this year and...

We are pleased to announce that the U.S. Food and Drug Administration (FDA) amended Biomeme’s SARS-CoV-2 Real-Time RT-PCR Test Emergency Use Authorization (EUA) for use with pooled samples in...

This is a very common question, so let’s get straight to it. There are 2 kinds of tests available for COVID-19: Direct Detection - tells you if portions of the SARS-CoV-2 virus were detected in your...

With support from the Cross-Border Threat Screening and Supply Chain Defense Center of Excellence, Biomeme and Predigen were proud to recently participate in discussion and demonstration of our work...

EDIT: As RNA viruses like SARS-CoV-2 continue to mutate, so will this panel. Please review our COVID-19 page for the latest information regarding our testing capabilities, including variant/mutation...

Biomeme has officially outgrown its home at 10th and Chestnut and is moving on to Netrality’s 401 North Broad Street for its new corporate headquarters! The new headquarters boasts 44,000 square feet...